Naratuximab emtansine (Nara; Debio 1562, formerly IMGN529) in combination with rituximab (Rituxan) showed deep responses and a duration of response that was not reached in patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL), according to findings from a phase 2 trial (NCT02564744) presented during the European Hematology Association (EHA) 2021 Virtual Congress.1
Moshe Yair Levy, MD, director of hematologic malignancies research, Texas Oncology-Baylor Charles A. Sammons Cancer Center, suggested during the presentation that the combination regimen could be a new treatment option for patients with relapsed/refractory DLBCL, including frail and heavily pretreated patients.
Naratuximab emtansine is an antibody-drug conjugate (ADC) comprised of the humanized anti-CD37 antibody K7153A, which is conjugated through a thioether-based linked to the cytotoxic maytansinoid DM1. CD37 is a surface marker on B lymphocytes and is highly expressed in non-Hodgkin lymphomas (NHLs). Its also an intern Thierry Facon, MD alizable cell surface antigen, which lends itself well to an antibody-drug construct, Levy noted. Nara is the most advanced CD37-targeted antibody-drug conjugate in clinical development in diffuse large B-cell lymphoma.
Previously in a phase 1 study (NCT01534715), naratuximab emtansine monotherapy showed a manageable safety profile and an objective response rate (ORR) of 22% in patients with DLBCL.2
But what they found is that if you co-administer this ADC with rituximab, you're actually going to get more internalization of the CD37 monoclonal antibody, therefore more payload delivered to your target cells. So, this led to this phase 2 study, Levy said.
The open-label, multicenter phase 2 study had an adaptive design.1 The safety run-in in part 1 included patients with relapsed/refractory NHL, including 9 with DLBCL and 8 with other NHLs. Patients were treated with 0.7 mg/kg naratuximab emtansine every 3 weeks on day 1 of the cycle followed by rituximab 375 mg/m2. This was followed by a run-in expansion with 2 cohorts including 8 patients with relapsed/refractory DLBCL in cohort 1 and 12 patients with other NHLs in cohort 2, all treated at the same schedule.
In part 2 of the study, only patients with DLBCL were enrolled and were treated with different dose schedules in the 2 cohorts. In cohort A, 33 patients were treated at the same every 3 week schedule and in cohort B, 30 patients were treated on a weekly schedule with 0.4 mg/kg naratuximab emtansine on day 1 of the 3-week cycle as well as on days 8 and 15 at 0.2 mg/kg followed by rituximab 375 mg/m2 on day 1.
ORR by Lugano classification was the primary end point, and other trial objectives were safety in terms of treatment-emergent adverse events (TEAEs), changes in laboratory tests, and changes in ECG and vital signs.
The overall trial enrolled patients with an ECOG performance status of 0 to 2 who had received 1 to 6 prior lines of treatment. Those with central nervous system (CNS) lymphomas were excluded, but patients with double- or triple-hit lymphoma, bulky disease, and transformed lymphoma were eligible for enrollment. Additionally, there were no limits on life expectancy in the trial, so it was a very inclusive type of study, according to Levy.
In part 1, patients were required to have a confirmed diagnosis of relapsed/refractory NHL, including DLBCL, follicular lymphoma, mantle cell lymphoma, and marginal zone lymphoma. Prior allogeneic stem cell transplant was not allowed. Then in part 2, patients were required to have a confirmed diagnosis of relapsed/refractory DLBCL and ineligibility for stem cell transplant.
Patients in the study ranged from 29 to 88 years old and were mostly male with Ann Arbor stage III or IV disease and extra-nodal disease involvement. In patients with DLBCL treated with the every-3-week schedule, the median number of prior therapies was 2, and 1 among patients treated with the weekly regimen. Forty percent of patients were refractory to their last treatment in the every-3-week group and 13.3% were refractory in the weekly group.
As of data cutoff on January 13, 2021, 36.0% of patients with DLBCL treated every 3 weeks in cohort A had completed 6 cycles of treatment, as did 50% treated with weekly naratuximab emtansine in cohort B, and 60% of patients with NHL treated every 3 weeks in cohort 2. After 6 cycles, patients could request an extension.
The median number of treatment cycles was 3 (range, 1-38) in cohort A, 5.5 (range, 1-30) in cohort B, and 7 (range, 1-52) in cohort 2. Discontinuation of both drugsas protocol designated that if naratuximab emtansine was to be discontinued, rituximab would be as wellwas primarily due to progressive disease across the study groups; adverse events leading to death were reported in 2 patients.
Of the 76 evaluable patients with DLBCL, the ORR was 44.7% and complete responses (CRs) were reported in 31.6%. In cohort A, the ORR was 50% and CRs were observed in 43.3%. In cohort B, the ORR was also 50% and CRs were reported in 33.3%.
Among patients with non-bulky DLBCL, the ORR was 50.8%. Patients treated in the third line or beyond who were not primary refractory showed an ORR of 46.4% and a CR rate of 32.1%.
The median duration of response was not reached after a median of 15 months of follow-up (95% CI, 9-18). Sixty-six percent of responders had a response lasting more than a year.
Grade 3/4 TEAEs were mostly hematologic and manageable, including most commonly neutropenia (54.0%), leukopenia (19.0%), lymphopenia (17.0%), and thrombocytopenia (12.0%). Additionally, 3 grade 3 liver TEAEs and 2 grade 3 non-serious neuropathy cases were reported.
He noted that no granulocyte colony stimulating factor was mandated in the trial; if it was, we probably would have seen a difference in the toxicity profile from the complication of cytopenias.
Grade 5 TEAEs were reported in 10 patients, only 2 of these, however, were considered related to treatment. Common serious adverse events included pneumonia/lung infection (5.0%), febrile neutropenia (4.0%), and general physical health deterioration (3.0%). Eight patients discontinued treatment due to a TEAE and 6 patients required a dose reduction.
[This] speaks to just how fragile this group of patients was, and the rather liberal inclusion criteria that allowed people irrespective of the amount of time we thought they had left, Levy said.
This is, in my viewpoint, very exciting therapy, Levy said. Clearly we have a need for another target in diffuse large B-cell lymphoma, and this certainly seems to compare quite favorably to other ADCs that we have seen in the space.
References
1. Levy MY, Grudeva-Popova Z, Trneny M, et al. Safety and efficacy of CD37-targeting naratuximab emtansine plus rituximab in diffuse large b-cell lymphoma and other non-hodgkins b-cell lymphomas a phase 2 study. Presented at: 2021 EHA Congress; June 9-17, 2021; Virtual. Abstract LBA1903.
2. Stathis A, Flinn IW, Madan S, et al. Safety, tolerability, and preliminary activity of IMGN529, a CD37-targeted antibody-drug conjugate, in patients with relapsed or refractory B-cell non-Hodgkin lymphoma: a dose-escalation, phase I study. Invest New Drugs. 2018;36(5):869-876. doi:10.1007/s10637-018-0570-4
Go here to read the rest:
Naratuximab Emtansine With Rituximab Leads to Durable Responses in R/R DLBCL - Targeted Oncology
- Chuck Chan, stem cell researcher who discovered how to regrow cartilage, dies at 48 - Palo Alto Online - May 4th, 2024
- Stem Cell and Platelet Rich Plasma Alopecia Therapies Market Analysis and Future Outlook by 2030 - openPR - May 4th, 2024
- Opinion: As stem cell biologists, we're concerned a Utah law will lead to a boom in snake oil sales - Salt Lake Tribune - May 2nd, 2024
- Robert Hariri: Developing Cost-Effective Cell Therapies From Placentas - BioSpace - May 2nd, 2024
- USC-led study introduces a new and improved way to grow the cells that give rise to the kidney's filtration system - EurekAlert - May 2nd, 2024
- Using stem cell-derived heart muscle cells to advance heart regenerative therapy - Medical Xpress - April 28th, 2024
- John Cleese is spending thousands on stem cell therapy is it really the secret to anti-ageing? - Yahoo Lifestyle Australia - April 28th, 2024
- SUM Hospital conducts Odishas first stem cell transplantation - The Times of India - April 24th, 2024
- Cancer treatment: What is stem cell therapy, and how does it work? - Moneycontrol - April 24th, 2024
- The murky, unregulated world of anti-ageing stem cell therapy - The Telegraph - April 24th, 2024
- Drug Prototype Promising in Treatment of Pulmonary Disease - Medscape - April 20th, 2024
- Man Paralyzed In Surfing Accident Regains Ability to Walk After Stem Cell Treatment - The Inertia - April 20th, 2024
- Medical breakthrough: 8-year-old boy first in New York to receive FDA-approved gene therapy for rare inherited blood disorder - WABC-TV - April 20th, 2024
- Stem Cell Treatment Helped A Man Who Was Paralyzed From The Neck Down To Stand On His Own - Bored Panda - April 20th, 2024
- UM, CUHK jointly hold symposium on stem cells and regenerative medicine - gcs.gov.mo - April 20th, 2024
- Paralysed patient now able to walk as stem cell therapy shows promising results - WION - April 15th, 2024
- Andrew Steele Sees Aging as the Root of Disease - Worth - Worth Magazine - April 15th, 2024
- The astonishing effect of stem cell implants - as groundbreaking treatment 'transforms' life for those with brain damage ... - Daily Mail - April 15th, 2024
- Consumer Alert on Regenerative Medicine Products Including Stem Cells - FDA.gov - April 13th, 2024
- This Startup Wants To Be OpenAI Of Stem Cell Therapy, Targets $250B Market - Forbes - April 13th, 2024
- Brain-cell transplants are the newest experimental epilepsy treatment - MIT Technology Review - April 3rd, 2024
- Global Regenerative Medicine Market to Touch Valuation of USD 472.95 Billion by 2032, at 25.86% CAGR: Astute ... - Yahoo Finance - April 1st, 2024
- Explosive Growth Projected for Stem Cell Market, Expected to Surpass $37 Billion by 2030 As Revealed In New... - WhaTech - April 1st, 2024
- Integrating New Therapies With Autologous Stem Cell Transplant in Myeloma - Targeted Oncology - April 1st, 2024
- New tool provides researchers with improved understanding of stem cell aging in the brain - Medical Xpress - March 30th, 2024
- The ISSCR announces 2024 election results - EurekAlert - March 28th, 2024
- Exosomes and Stem Cells Are the Future of Anti-Aging - NewBeauty Magazine - March 28th, 2024
- Charles River Extends Gene Therapy Alliance with NUS Medicine - Contract Pharma - March 22nd, 2024
- Exciting opportunities in stem cell technology and regenerative biology in Indian healthcare industry - Express Healthcare - March 22nd, 2024
- Charles River Announces Extension of Gene Therapy Manufacturing Alliance with NUS Yong Loo Lin School of Medicine - Yahoo Finance - March 22nd, 2024
- Opinion: The revolutionary sickle cell therapies - MSN - March 22nd, 2024
- 10 Years of Kansas Regenerative Medicine Center - KSAL - March 22nd, 2024
- BioCardia and StemCardia Announce Biotherapeutic Delivery Partnership - Diagnostic and Interventional Cardiology - March 17th, 2024
- Cynata Therapeutics' breakthrough in regenerative medicine - Finance News Network - March 17th, 2024
- New Positive Data Presented on Briquilimab Conditioning in Patients with Fanconi Anemia - GlobeNewswire - March 17th, 2024
- Novel 3D stem cell therapy to treat critical limb ischaemia - Drug Target Review - March 15th, 2024
- Breaking Boundaries: Pharmicell's Bold Vision for Healthcare Transformation and Monumental Growth - The Worldfolio - March 15th, 2024
- CuSTOM Organoid Research Evolving From Tool to Treatment - Research Horizons - Research Horizons - March 15th, 2024
- BioCardia and StemCardia Announce Partnership to Deliver Cell-Gene Therapy for Remuscularization of Heart - Cath Lab Digest - March 15th, 2024
- Calidi Biotherapeutics and City of Hope Announce Funding from the California Institute for Regenerative Medicine ... - Business Wire - March 13th, 2024
- Iron restriction keeps blood stem cells young, researchers find - Phys.org - March 13th, 2024
- Vitamin A could have a key role in both stem cell biology and wound healing: Study - Medical Dialogues - March 9th, 2024
- Trends in Stem Cell Transplantation Refusal for Myeloma Treatment - Targeted Oncology - March 7th, 2024
- Stem Cell Therapy Market (CAGR) of 31.1%, Future of Market Size Emerging Technologies and their Impact on ... - Taiwan News - March 7th, 2024
- This Swedish startup wants to reduce the cost, and controversy, around stem cell production - TechCrunch - March 6th, 2024
- Advancing stem cell therapy: The regulatory process to get to clinical trials - The Economic Times - March 6th, 2024
- Transitioning from traditional surgical methods to the innovative use of stem cells - pharmaphorum - March 6th, 2024
- 'Mini organs' are grown from human stem cells taken during the late stages of pregnancy for the first time - m - Daily Mail - March 6th, 2024
- Stem cell transplant cures man of HIV and leukemia, one of five to achieve full remission - Fox 28 - March 3rd, 2024
- Stem Cell Therapy Market to Boost USD 137.5 Billion by 2034 and Projected to grow at 32.10% CAGR with increasing ... - Yahoo Finance - March 1st, 2024
- Studies expand use of stem cell therapies - WPLG Local 10 - March 1st, 2024
- Innovative therapy targets and destroys leukemia stem cells - News-Medical.Net - February 27th, 2024
- Unlocking the Potential of Stem Cells: The Medical Revolution of the Century - EIN News - February 27th, 2024
- Pelage Pharmaceuticals Announces $16.75M Series A Financing led by GV to Revolutionize Regenerative Medicine ... - Yahoo Finance - February 27th, 2024
- Say Her Name - Henrietta Lacks, The Real Mother Of Stem - Her Campus - February 27th, 2024
- California Man Free of HIV And Cancer in Astonishing Medical Recovery - ScienceAlert - February 25th, 2024
- $93 million for research into improved health for children, young people and the aged, medical devices, mental health ... - Department of Health - February 25th, 2024
- Stem Cells in Regenerative Medicine - PMC - National Center for ... - February 24th, 2024
- The Promise and Reality of Stem Cell Therapy: What You Need to Know - Corporate Wellness Magazine - February 22nd, 2024
- Stem Cell Therapy: A Beacon of Hope for Patients with Untreatable Conditions - Corporate Wellness Magazine - February 22nd, 2024
- Leading Experts in Stem Cell Therapy: A Global Overview - Corporate Wellness Magazine - February 22nd, 2024
- Can Stem Cells Help Reverse the Effects of Aging? - Corporate Wellness Magazine - February 22nd, 2024
- Stem Cell Therapy for Cancer: Hope on the Horizon? - Corporate Wellness Magazine - February 22nd, 2024
- Stem Cells and Autism: A Closer Look at Innovative Treatments - Corporate Wellness Magazine - February 22nd, 2024
- Regrowth and Restoration: The Science Behind Stem Cell Therapy for Hair - Corporate Wellness Magazine - February 22nd, 2024
- Brain Recovery: The Role of Stem Cells in Stroke and Cerebral Palsy Treatments - Corporate Wellness Magazine - February 22nd, 2024
- Turning Back the Clock: The Science of Stem Cells in Anti-Aging - Corporate Wellness Magazine - February 22nd, 2024
- Insights into cellular therapies for cancer treatment - Drug Target Review - February 22nd, 2024
- The Role of Stem Cells in Rheumatoid Arthritis Recovery - Corporate Wellness Magazine - February 22nd, 2024
- Dr Ernesto Romeros vision transforms immunotherapy regenerative medicine into a global leader in stem cell treatment - Khaleej Times - February 22nd, 2024
- World-Renowned Doctors Leading the Way in Stem Cell Research and Treatment - Medical Tourism Magazine - February 20th, 2024
- Choosing the Best: A Guide to America's Premier Stem Cell Therapy Providers - Medical Tourism Magazine - February 20th, 2024
- Navigating Through the Possibilities of Stem Cell Treatment for Eye Disorders - Medical Tourism Magazine - February 20th, 2024
- Global Leaders in Stem Cell Therapy: Where Excellence Meets Innovation - Medical Tourism Magazine - February 20th, 2024
- Excellence in Stem Cell Treatment: How the US is Pioneering Global Healthcare Solutions - Medical Tourism Magazine - February 20th, 2024
- Clarifying Memory Loss Treatments: The Role of Stem Cells - Medical Tourism Magazine - February 20th, 2024
- Battling Inflammation: Stem Cell Therapy for Rheumatoid Arthritis - Medical Tourism Magazine - February 20th, 2024
- Digestive Health and Stem Cells: Treating Ulcerative Colitis and Crohn's Disease - Medical Tourism Magazine - February 20th, 2024
- Top Stem Cell Clinics in the USA: Pioneering Treatments for Chronic Conditions - Medical Tourism Magazine - February 20th, 2024
- Stem Cells and Autism: Understanding the Potential for Innovative Treatments - Medical Tourism Magazine - February 20th, 2024
Recent Comments